Associated tags: Biomarker, Frontotemporal dementia, DSM-IV codes, Alector, ALEC, Pharmaceutical industry, SAN, Immune system, Neurodegeneration, Vaccine
Locations: EUROPE, UNITED STATES, NORTH AMERICA, ARGENTINA, SOUTH SAN FRANCISCO, CA, US, AD, MAB
Retrieved on:
Wednesday, February 28, 2024
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
Key Points:
- SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
TD Cowen 44th Annual Health Care Conference (Boston, Massachusetts)
Leerink Partners Global Biopharma Conference (Miami, Florida)
Barclays 26th Annual Global Healthcare Conference (Miami, Florida)
A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com.
- Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.
Retrieved on:
Tuesday, February 27, 2024
PD,
GSK,
Arnon Rosenthal,
Investment,
Interest,
ARIA,
AbbVie,
Webcast,
Plasma,
PET,
MRI,
Central nervous system,
Traffic barrier,
GPNMB,
Cerebrospinal fluid,
Breakthrough therapy,
ALEC,
Frontotemporal dementia,
FTD,
DSM-IV codes,
European Medicines Agency,
Food and Drug Administration,
Canadian International Council,
Brain,
SAN,
Total,
LTE,
Amyloid-related imaging abnormalities,
Alector,
ALS,
AAIC,
PROGRESS,
ABC,
Manuscript,
Conference,
Safety,
Biomarker,
Patent,
CSF,
Mutation,
IND,
Microglia,
European Patent Convention,
Insurance,
PIN,
FDA,
Food,
Risk,
TREM2,
Dementia,
Disease,
Pharmaceutical industry Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
Key Points:
- Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
- In September 2023, Alector completed enrollment of 381 participants in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial.
- In July 2023, Alector presented an update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC).
- Alector’s management team will host a conference call discussing Alector’s results for the fourth quarter and full year 2023 and provide a business update.
Retrieved on:
Tuesday, February 20, 2024
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Tuesday, February 27, 2024, at 4:30 p.m.
Key Points:
- SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Tuesday, February 27, 2024, at 4:30 p.m.
- ET to discuss results for the fourth quarter ended December 31, 2023, and provide a full-year business update.
- A press release detailing fourth quarter results will be issued prior to the call.
- Interested parties participating by phone will need to register using this online form .
Retrieved on:
Thursday, February 8, 2024
Partnership,
Alector,
GSK plc,
SAN,
Deficit spending,
Patient,
Safety,
Cerebrospinal fluid,
CSF,
Brain,
Risk,
Plasma,
Arnon Rosenthal,
ALEC,
GSK,
Frontotemporal dementia,
PD,
Pharmaceutical industry Alector and GSK are co-developing and will be co-commercializing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
Key Points:
- Alector and GSK are co-developing and will be co-commercializing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
- We look forward to continuing the development of AL101 in this Phase 2 trial with our partner GSK who is operationalizing the trial.
- The primary endpoint of the study is disease progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB).
- The study results demonstrated that the PK and PD profile supported the progression to Phase 2 clinical trials for more prevalent neurodegenerative conditions, such as AD and Parkinson’s disease.
Retrieved on:
Wednesday, February 7, 2024
Partnership,
Alector,
GSK plc,
SAN,
FDA,
Neurodegenerative disease,
Food,
Arnon Rosenthal,
ALEC,
GSK,
Frontotemporal dementia,
Pharmaceutical industry SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to latozinemab, an investigational human monoclonal antibody designed to block sortilin to elevate progranulin (PGRN) levels for the potential treatment of frontotemporal dementia with a progranulin gene mutation (FTD-GRN).
Key Points:
- SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to latozinemab, an investigational human monoclonal antibody designed to block sortilin to elevate progranulin (PGRN) levels for the potential treatment of frontotemporal dementia with a progranulin gene mutation (FTD-GRN).
- “In partnership with GSK, we are encouraged and excited by this FDA Breakthrough Designation.
- FTD-GRN is a rare and rapidly progressing neurodegenerative disease and one of the most common causes of early onset dementia," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.
- Latozinemab, the most advanced progranulin-elevating candidate in clinical development for FTD-GRN, is currently being studied in the pivotal INFRONT-3 Phase 3 study, which achieved target enrollment in October 2023.”
The FDA granted latozinemab Breakthrough Therapy Designation for FTD-GRN based upon data from the INVOKE-2 Phase 2 clinical trial of latozinemab in FTD-GRN participants.
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its underwritten public offering of shares of its common stock.
Key Points:
- SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its underwritten public offering of shares of its common stock.
- Alector sold 10,869,566 shares of its common stock in the offering.
- Alector has granted the underwriter a 30-day option to purchase up to an additional 1,630,434 shares of its common stock.
- The gross proceeds to Alector from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are approximately $75 million.
Retrieved on:
Wednesday, January 17, 2024
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of $75 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Alector.
Key Points:
- SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of $75 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Alector.
- The offering is expected to close on January 19, 2024, subject to satisfaction of customary closing conditions.
- All of the shares in the offering are being sold by Alector.
- Alector has granted the underwriter a 30-day option to purchase up to an additional 1,630,434 shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts and commissions.
Retrieved on:
Tuesday, January 16, 2024
In connection with the proposed offering, Alector expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of its common stock offered in the public offering.
Key Points:
- In connection with the proposed offering, Alector expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of its common stock offered in the public offering.
- There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.
- All of the shares in the proposed offering are being sold by Alector.
- Cantor Fitzgerald & Co. is acting as sole book-running manager for the proposed offering.
Retrieved on:
Tuesday, November 28, 2023
SOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the Company’s TREM2 and progranulin (PGRN) programs.
Key Points:
- SOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the Company’s TREM2 and progranulin (PGRN) programs.
- The events will include presentations from Alector’s management as well as leading scientific and clinical experts who will provide their perspectives on the biological and genetic rationale for the TREM2 and PGRN targets, share an overview of the current treatment landscapes for frontotemporal dementia and Alzheimer’s disease, and discuss the significant unmet needs that remain in the treatment of these neurodegenerative diseases.
- To access the live webcasts of these events, please register here for TREM2 and here for PGRN, or visit “Events and Presentations” in the “Investors” section of the Alector website at https://investors.alector.com .
- An archived replay will be available for approximately 90 days following each presentation.
Retrieved on:
Wednesday, November 8, 2023
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 11:30 a.m.
Key Points:
- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 11:30 a.m.
- ET.
- A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com .
- A replay will be available on the Alector website for 90 days following the event.
